Show simple item record

dc.contributor.authorSanford, Sophie AI
dc.contributor.authorMcEwan, William
dc.date.accessioned2022-06-16T23:30:27Z
dc.date.available2022-06-16T23:30:27Z
dc.date.issued2022
dc.identifier.issn1662-5102
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/338174
dc.description.abstractThe detection of pathogen-associated molecular patterns can elicit the production of type-I interferons (IFNs), soluble cytokines that induce a transcriptional state inhibitory to viral replication. Signatures of type-I IFN-driven gene expression, and type-I IFNs themselves, are observed in the central nervous system during neurodegenerative diseases including Alzheimer's disease and other tauopathies, the umbrella term for diseases that feature aggregation of the cytosolic protein tau. The contribution of the type-I IFN response to pathological progression of these diseases, however, is not well-understood. The wholesale transcriptional changes that ensue from type-I IFN production can both promote protective effects and lead to damage dependent on the context and duration of the response. The type-I IFN system therefore represents a signaling pathway with a potential disease-modifying role in the progression of neurodegenerative disease. In this review we summarize the evidence for a type-I IFN signature in AD and other tauopathies and examine the role of aggregated proteins as inflammatory stimuli. We explore both the protective role of IFN against protein pathologies as well as their downstream toxic consequences, which include the exacerbation of protein pathology as a potentially destructive feed-forward loop. Given the involvement of type-I IFNs in other neurogenerative diseases, we draw comparisons with other categories of homotypic protein aggregation. Understanding how type-I IFN influences progression of AD and other tauopathies may yield important insight to neurodegeneration and identify new targets in an area currently lacking disease-modifying therapies.
dc.description.sponsorshipAlzheimer's Society studentship 488 Wellcome Trust and Royal Society Sir Henry Dale Fellowship 206248/Z/17/Z UK Dementia Research Institute Fellowship Lister Institute of Preventative Medicine
dc.publisherFrontiers Media SA
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleType-I Interferons in Alzheimer's Disease and Other Tauopathies.
dc.typeArticle
dc.publisher.departmentDepartment of Clinical Neurosciences
dc.date.updated2022-06-16T13:04:10Z
prism.publicationNameFront Cell Neurosci
dc.identifier.doi10.17863/CAM.85585
dcterms.dateAccepted2022-06-16
rioxxterms.versionofrecord10.3389/fncel.2022.949340
rioxxterms.versionAM
dc.contributor.orcidMcEwan, William [0000-0002-4408-0407]
dc.identifier.eissn1662-5102
rioxxterms.typeJournal Article/Review
pubs.funder-project-idWellcome Trust (206248/Z/17/Z)
pubs.funder-project-idLister Institute of Preventive Medicine (Unknown)
pubs.funder-project-idAlzheimer's Society (488 (AS-PhD-18b-018))
pubs.funder-project-idUK Dementia Research Institute (Unknown)
cam.issuedOnline2022-07-15
cam.orpheus.successWed Aug 03 09:45:52 BST 2022 - Embargo updated
cam.orpheus.counter4
cam.depositDate2022-06-16
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
rioxxterms.freetoread.startdate2022-07-15


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International